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Oral cancer is of major public health problem in India. Current investigation was aimed to identify 
the specific deregulated miRNAs which are responsible for development of resistance phenotype 
through regulating their resistance related target gene expression in oral squamous cell carcinoma 
(OSCC). Cisplatin-resistant OSCC cell lines were developed from their parental human OSCC cell lines 
and subsequently characterised. The resistant cells exhibited enhanced proliferative, clonogenic 
capacity with significant up-regulation of P-glycoprotein (ABCB1), c-Myc, survivin, β-catenin and a 
putative cancer-stem-like signature with increased expression of CD44, whereas the loss of E-cadherin 
signifies induced EMT phenotype. A comparative analysis of miRNA expression profiling in parental 
and cisplatin-resistant OSCC cell lines for a selected sets (deregulated miRNAs in head and neck cancer) 
revealed resistance specific signature. Moreover, we observed similar expression pattern for these 
resistance specific signature miRNAs in neoadjuvant chemotherapy treated and recurrent tumours 
compared to those with newly diagnosed primary tumours in patients with OSCC. All these results 
revealed that these miRNAs play an important role in the development of cisplatin-resistance mainly 
through modulating cancer stem-cell-like and EMT-type properties in OSCC.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide1. It is one of the 
most prevalent and leading cancers in India2. It accounts for over 30% of all cancers reported in the country3. In 
head and neck cancers, oral squamous cell carcinoma (OSCC) arises from the epithelial lining of the oral cavity, 
pharynx, larynx and it accounts 90–94% of all oral cancers4. Although, smoking is a primary risk factor for oral 
cancers, the other etiological factors include the use of alcohol, areca nut, betel leaf in addition to human papil-
lomavirus (HPV) infection2,3. The treatment of OSCC involves surgery, radiotherapy and chemotherapy. Despite 
advancement in both diagnosis and therapy in recent years, the prognosis and 5-year survival rate of OSCC 
remains same at around 50%5. Fatal outcome is mainly caused by local recurrence and cervical (neck) lymph 
node metastasis and occasionally by distant organ metastasis. Nonetheless, due to their heterogeneous charac-
ter, it is difficult to distinguish good prognostic tumour from more-aggressive poor prognostic tumour which 
shows therapy resistance and subsequently relapses and metastasizes5. In this patient subgroup (poor prognostic) 
the selection of pre-existing tumourogenic resistant cells or the cancer-stem-cells (CSCs) and/or acquisition of 
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resistant cells during treatment with chemo-radiation therapy has been anticipated6. The drug-resistance is medi-
ated either with the over-expression of multidrug resistance (MDR) related ABC-transporters, growth factor 
receptors, or through acquisition of cancer stem-cell-like (CSC), epithelial-mesenchymal transition (EMT) prop-
erties and activation of DNA-repair mechanism7–10. Subsequently, deregulated miRNAs play an important role in 
the regulation of tumour recurrence and metastasis11,12. Moreover, the exposures to environmental toxic agents 
(smoking) are able to alter miRNA expression and thus implicating them in cancer development13. However, the 
involvement of miRNAs in the development of drug-resistance in OSCC has not been understood clearly.
In the present study we have developed two cisplatin-resistant OSCC cell lines that provided an insight into 
the drug resistant phenotype in oral cancer. We found together with the activation of the drug resistance the 
enrichment of cancer stem-cell-like property coupled with augmentation of EMT phenotype in OSCC cell lines. 
We further identified a miRNA expression signature associated with the drug resistance property of these cell 
lines. Consequently, we have checked the expression level of these miRNAs in OSCC-patient sub-groups like pri-
mary tumour, neoadjuvant chemotherapy treated tumour and recurrent tumour. In this study, we aim to under-
stand the molecular pathways by which enrichment of cancer-stem-cell markers associated with induced EMT 
occurs in these cell lines anticipating that it might have a role in therapeutic outcome, metastasis and tumour 
recurrence.
Results
Cisplatin-resistant cells confer resistance to cisplatin-induced-cytotoxicity. Preliminary infor-
mation on two oral squamous cell carcinoma cell lines UPCI: SCC084 and UPCI: SCC131 (hereafter referred to 
as SCC084 and SCC131) is given in the Supplementary Table S114. Cisplatin resistant cell lines, SCC084/R and 
SCC131/R were developed by incremental doses of cisplatin treatment in successive passages for 6 months (see 
material and method section) from their parental cell line, SCC084 and SCC131 and maintained in presence 
of 3 μM cisplatin. Cell lines were exposed to various concentrations (1 μM to 20 μM) of cisplatin for different 
time points (24 h, 48 h, and 72 h) to determine the cisplatin-induced-cytotoxicity. The cell viability profile of the 
cisplatin-resistant (SCC084/R and SCC131/R) and their parental (SCC084 and SCC131) cell lines are shown in 
Fig. 1A. The IC50 value of SCC084/R and SCC131/R cells were increased by 1.6 and 3.5 fold (R index) upon 72 h 
incubation with cisplatin respectively as compared to their parental cells corroborating the fact that the number 
of viable cells is significantly high in cisplatin-resistant cells (Fig. 1A, Supplementary Table S2). Moreover, the 
results also revealed that the parental SCC084 cell itself, originated from a recurrent tumour, was more resistant to 
cisplatin and it showed approximately 3.5 fold higher (at 72 h) IC50 value compared to the SCC131 cell line which 
was originated form a primary tumour (Supplementary Table S2).
We also determine the cisplatin-induced-cytotoxicity of these OSCC cell lines by monolayer colony formation 
assay at two different doses of cisplatin: 3 μM (in which the resistant cell lines were maintained) and 10 μM (a 
much higher dose than the IC50 values of cisplatin-resistant cells at 72 h). The results showed that pre-treatment 
with cisplatin for 24 h significantly increased the colony formation efficiency and number of colonies after 
14 days in cisplatin-resistant cells than those of their parent cells (Fig. 1B,C). Interestingly we observed that 
cisplatin-resistant and sensitive cells have distinct cellular morphology. The compactness of the colonies was 
reduced and loosely dispersed in case of resistant cells. The shape and size were also significantly changed in 
cisplatin-resistant cells compare to parent cells. The morphologically heterogeneous population could also be 
frequently recognised in resistant cell-colonies especially in SCC131/R cell colonies (Fig. 1D).
Cisplatin-induced apoptosis is significantly abrogated in the resistant OSCC cells. Next we per-
formed the following experiments to elucidate cisplatin-resistant OSCC cell lines exhibit attenuated apoptosis 
upon drug treatment. The FACS analysis of annexin V-FITC and propidium iodide (PI) stained cells showed that 
cisplatin mediated apoptotic cell (both annexin V-FITC positive and annexin V-FITC/PI positive) population 
was significantly high in parental, SCC084 and SCC131 cells compared to the resistant, SCC084/R and SCC131/R 
cells (Fig. 2A,B). FACS analysis was also employed to determine the effect of cisplatin on the cell cycle phase dis-
tribution of both resistant and sensitive cell lines. The appearance of sub-diploid phase (sub G1/G0) is a specific 
marker of apoptosis. The significant increase in the counts of sub diploidal cells in a dose dependent fashion were 
found only in sensitive SCC084 and SCC131 cells compared to the untreated control and the resistant, SCC084/R 
and SCC131/R cells (Fig. 2C,D). Further to prove the differential response of OSCC resistant cells to cisplatin, 
we evaluated the caspase-3 and PARP1 cleavage in these cell lines by western blot analysis (Fig. 2E,F). Our data 
revealed that both caspase-3 and PARP1 cleavages were distinct after treatment of cisplatin for 72 h in SCC084 
and SCC131 cells compared to that of resistant cells SCC084/R and SCC131/R (Fig. 2E: representative data for 
Caspase-3 cleavage in SCC084 cell line and Fig. 2F: representative data for PARP1 cleavage in SCC131 cell line). 
Collectively, these observations revealed that SCC084/R and SCC131/R cells confer resistance by abrogating the 
cisplatin-induced apoptosis.
Molecular characterisation of cisplatin-resistant cells. A diverse range of molecular mechanisms 
have been implicated in acquired-drug resistance8,9. The overexpression of drug efflux pump (ABC-transporter) 
is frequently associated with drug resistance phenotype8. To investigate the molecular mechanism of acquired 
resistance to cisplatin in these cell lines SCC084/R and SCC131/R, first we checked for differential changes (if 
any) in expression of different ABC-transporters. We have found that P-gp (ABCB1) and MRP1 (ABCC1) expres-
sion were significantly increased in SCC131/R cells compared to the parental SCC131 cells but the similar obser-
vation was not true for SCC084/R and SCC084 cells when analysed by using the FACS, confocal microscopic 
analysis (for both P-gp and MRP1) and quantitative real-time PCR (for P-gp) (Fig. 3A–D). Doxorubicin accu-
mulation study corroborates our results and revealed that doxorubicin accumulation was significantly reduced 
in SCC131/R cells compared to SCC131 cells (Fig. 3E). However, another important transporter ABCG2 was not 
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changed significantly in both the cisplatin-resistant cell lines as we have checked this at mRNA level (real-time 
PCR) (Fig. 3B,C).
Next we screen for some pathway specific proteins like survivin (encoded by BIRC5), β -catenin (encoded 
by CTNNB1) and NOTCH1 in these cisplatin-resistant cell line. Remarkably, we have found that both survivin 
and β -catenin were significantly up-regulated at the mRNA and protein level in both the cisplatin resistant cells 
(Fig. 3D–G) but no significant change was found in NOTCH1 (mRNA level) expression (Fig. 3D,E). All these 
results suggested that although the survival mechanisms are upregulated by increasing the level of survivin and 
β -catenin in both the resistant cell lines but the overall resistance mechanisms are not same for two different 
cisplatin-resistant OSCC cell lines.
Cisplatin-resistant OSCC cells demonstrate enhanced cancer-stem-cell (CSC)-like property. 
Since, stem-cell-like cancer cells are believed to be coupled with drug-resistant property9,15,16; here we tried to find 
out that if any stem-cell-like feature present in these cisplatin-resistant OSCC cell lines. The results of the sphere 
forming assay revealed that the tumour sphere forming-ability was significantly increased in cisplatin-resistant 
SCC084/R and SCC131/R cells compared to parental SCC084 and SCC131 cells. The number and size of the 
sphere was increased drastically in both cisplatin-resistant cell lines within 7 days (Fig. 4). The consequences 
imply that cisplatin-resistant cells are enriched in self-renewing cells as evidenced by their greater ability to sur-
vive in tumourosphere condition.
Moreover, the western blot analysis also revealed resistant cells displayed increased expression of 
cancer-stem-cell markers than the parental cells. CD44 and c-Myc protein expression were significantly increased 
in SCC084/R cells while c-Myc and Oct-4 proteins were significantly increased in SCC131/R cells compared to 
SCC084 and SCC131 respectively (Fig. 5A,B). However, Sox-2 protein expression didn’t show any significant 
Figure 1. Cytotoxic effect of cisplatin on cisplatin-resistant (SCC131/R and SCC084/R) and their parental 
(SCC131 and SCC084) OSCC cells lines. (A) Dose response curves of cell viability for cisplatin using SCC131, 
SCC131/R (upper panel), and SCC084, SCC084/R (lower panel) cells for different time point (24 h: •, 48 h: ♦ , 
72 h:  ) as assessed by MTT assay. Cell viability was determined as percentage of untreated control cells. Value 
represents the mean ± SE of three independent experiments with four replicates in each. (B,C) Cytotoxicity of 
cisplatin in resistant and parental SCC131 (B) and SCC084 (C) cells was also determined by monolayer colony 
formation assay. Clonogenicity of cells was affected by different doses of cisplatin as seen in the plates (upper 
panel). The colonies were counted from three independent experiments using Image J software and plotted as 
mean ± SE (lower panel). *p < 0.05, **p < 0.01, ***p < 0.001 (D) Untreated parental and resistant cell colonies 
(upper panel for SCC084 and lower panel for SCC131) were evaluated and found with distinct morphological 
differences using light microscope (10X magnification). Resistant cells were composed mainly of spindle-
shaped cells along with heterogeneous population compared to the parental cells.
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change in both the resistant cell lines (Fig. 5A,B). All these results revealed that both the cisplatin-resistant OSCC 
cells are significantly associated with induced CSC-like characteristics compared to their parental counterpart.
Resistant cell lines display induced EMT (epithelial-mesenchymal transition). Augmented 
sphere-forming ability and CSC-marker expression in the cisplatin-resistant cells as well as distinct change in 
cellular-morphology lead us to speculate whether there is any change in the expression of EMT-markers15–17 
and hence in cellular migration. To confirm the induction of EMT in cisplatin-resistant cells, we analyze the 
expression of E-cadherin15,17 protein using western blot in comparison to parental-sensitive cells. The level of 
E-cadherin expression in resistant cells was significantly decreased compared to that of parental cells (Fig. 5C,D). 
Another protein involucrin whose expression is known to correlate with the degree of differentiation18, is also 
considerably reduced in cisplatin-resistant cell lines compared to parental cell lines (Fig. 5C,D). Another impor-
tant EMT-related gene, BMI115,16 and MMP915,16,19 expressions were also evaluated at mRNA level by qRT-PCR 
in these cell lines. The results revealed that BMI1 expression was significantly increased in both the resistant cell 
line whereas MMP9 expression was remarkably increased only in SCC131/R cells compared to respective parental 
cells (Fig. 5E). All these results suggested that in both the cisplatin-resistant cells EMT-phenotype are significantly 
increased compared to their parental counterpart. To substantiate our result further we intended to check the 
potential ability of cell migration in these cell lines by in vitro scratch assay. Interestingly, we discovered that irre-
spective of drug treatment the cellular migration was significantly increased in cisplatin-resistant cell line com-
pared to their parental-sensitive cells (Fig. 6). Therefore, the overall culmination revealed that cisplatin-resistant 
cell lines demonstrate significant induction in EMT as well as cellular-migration ability.
Figure 2. Cisplatin induces apoptosis in parental cells significantly compare to resistant OSCC cells. 
(A) Quantification of apoptosis by annexin V binding to SCC084 and SCC084/R cells. Cells were incubated 
with indicated doses of cisplatin for 48 h and then stained with annexin V-FITC/PI and analyzed by flow 
cytometry. (B) Bar diagram represent the mean ± SE calculated from three independent experiments. (C) Cell 
cycle distribution of SCC131 and SCC131/R cells following cisplatin treatment for 48 h. After staining with 
propidium iodide they were analyzed using a flow cytometer. (D) Each column represents the percentages of 
cells in sub-dipliodal (Sub-G0/G1) population of cell cycle at indicated time after treatment. Data represent the 
mean ± SE calculated from three independent experiments. (E) Representative image of caspase 3 cleavage 
by western blot using cleaved Caspase 3 antibody in SCC084 and SCC084/R cells. Cells were incubated with 
indicated doses of cisplatin for 48 h and then whole cell lysates analyzed by western blot for caspase 3 and 
cleaved caspase 3 protein product. α -Tubulin was used as a loading control. (F) Effect of cisplatin on the 
cleavage pattern of PARP1 in SCC131 and SCC131/R cells. Cells were incubated with indicated doses of 
cisplatin for 48 h and then whole cell lysates were for western blotting for cleaved and total PARP1 using specific 
antibody. α -Tubulin was used for normalization. For (A,C,E) and (F), images are representative of three 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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Cisplatin-resistant oral cancer cell lines exhibit distinct miRNA expression pattern with a com-
plex target gene regulatory-network. Next our specific aim was to identify the critical miRNAs those 
are involved in the development of cisplatin-resistant phenotype in oral cancer. We compared 52 miRNAs which 
are found to be deregulated in head and neck cancer malignancies (Supplementary Table S3). We extracted the 
list of miRNAs those are revealed by 6 different studies with tumour samples of head and neck cancer patients 
from PhenomiR Database v2.0 (as on May 2014)20. From the database we have found that, 15 miRNAs are down-
regulated whereas 37 miRNAs are upregulated among those 52 deregulated miRNAs in HNSCC (Supplementary 
Table S3). Two parallel sets of cisplatin-resistant and parental cell lines, (SCC084/R and SCC084) and (SCC131/R 
and SCC131) were profiled to identify miRNAs which are associated with the development of drug resistance in 
OSCC. The miRNA profiling of SCC084/R compared to SCC084 cells revealed that 36 miRNAs were differen-
tially expressed (p ≤ 0.05) and shown in the Fig. 7A and Supplementary Table S4. Conversely, the profiling also 
disclosed that 12 miRNAs are differentially expressed (p ≤ 0.05) in SCC131/R cells compared to SCC131 cells 
as summarised in the Fig. 7B and Supplementary Table S4. Finally, we have established 6 miRNA signatures 
(miR-130b, miR-134, miR-149, miR-491, miR-181d, miR-146b) which are significantly (p ≤ 0.05) differentially 
Figure 3. Changes in molecular properties of cisplatin-resistant cells (SCC131/R and SCC084/R) 
compared to their parental (SCC131 and SCC084) OSCC cells. (A) P-glycoprotein and MRP1 expression 
were significantly increased in SCC131/R cell line compared to the parental SCC131 cells but not in 
SCC084/R. Cells were stained with P-gp mouse monoclonal UIC2 followed by anti-mouse PE-conjugated 
secondary antibodies along with FITC-conjugated mouse monoclonal MRP-1 antibody and evaluated 
using FACS. (B) Representative image of confocal microscopy for P-gp and MRP expression in SCC131 and 
SCC131/R cells. Cells were stained same as FACS –staining except P-gp mouse monoclonal antibody C219 
for Confocal microscopic analysis. (C) Confocal microscopic images showing the doxorubicin accumulation 
was significantly reduced in SCC131/R cells compared to SCC131 cells. After seeding a day before cells were 
incubated with doxorubicin (10 μM) for 1 h at 37 °C then washed with PBS before glycerol mounting and 
analysed immediately for intracellular accumulation of doxorubicin using confocal microscope. (D,E) mRNA 
expression level of ABCG2, ABCB1 (P-gp), BIRC5 (survivin), CTNNB1 (β -catenin) and NOTCH1 in both the 
resistant (SCC131/R: D and SCC084/R: E) cells compared to their parental (SCC131: D and SCC084: E) cells. 
Total RNA isolated was reverse transcribed and the cDNA subjected to qRT-PCR using gene specific forward 
and reverse primers. Relative expression values were normalized to those of 18 s rRNA. (F) Western blot images 
showing the survivin and β -catenin protein expression were significantly increased in both resistant (SCC131/R 
and SCC084/R) cells compared to their parental cells (SCC131 and SCC084). Whole cell-lysates from different 
cell lines were subjected to western blot using specific antibodies. Relative expression values were normalized 
to those of β -actin. (G) Densitometric quantification of survivin and β -catenin protein band in resistant 
and parental cells. Immunoractive bands were quantified and expressed as the ratio of each band density to 
after normalization to loading control (β -actin) band density. For (D,E,G), data represent three independent 
experiments and expressed as mean ± SE. For (A–C,F), images are representative of three independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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expressed and common in both the cisplatin resistant cell lines (SCC084/R and SCC131/R) compared to their 
parental cell lines (SCC084 and SCC131) (Fig. 7C and Supplementary Table S5). Next, to confirm our in vitro cell 
line data, the expression status of these signature miRNAs were checked in few patient sub-groups comprised of 
primary tumours (PT; n = 6), neoadjuvant chemotherapy treated tumours (CT; n = 4) and recurrent tumours 
(RT; n = 5) in patients with OSCC (see Materials and Method section). Detailed patient history is provided in 
the Supplementary Table S6. Significant changes (significant p values given in Fig. 7D, Supplementary Table S7) 
in miRNA expression were observed in recurrent tumours when compared to primary tumours in patients with 
OSCC. Moreover, we confirmed the role of miR-134 in resistance development (randomly selected miRNA from 
those six signature miRNAs) through altering its endogenous expression by using its mimic and inhibitor in 
OSCC cell lines. The results revealed that both the parental cell lines (SCC084 and SCC131) showed significant 
increase in cisplatin-sensitivity and cisplatin-resistance along with overexpression and inhibition of endogenous 
miR-134 expression respectively in these OSCC cell lines (Fig. 7E). Similarly SCC131/R cell line displayed the 
significant changes in cisplatin-sensitivity/resistance whereas SCC084/R did not display any notable difference 
when we altered the level of miR-134 expression by using its mimic and inhibitor compared to the mock.
Further, we have explored the expression status of the target mRNA/genes (see material and method section) 
using the miRTarBase and ONCOMINE database21,22, of the deregulated miRNAs (36 unique and 6 common) 
observed in SCC084/R and SCC131/R cell lines. However, only 26 out of the 40 miRNAs (miR-181d and miR-
146b were excluded as they displayed opposite expression status in SCC084/R and SCC131/R) yielded experi-
mentally known target mRNAs. 100 experimentally known target genes are found to be upregulated while 44 are 
downregulated in multiple types of cancer cell lines (Supplementary Figure S1). Most of these target genes are 
involved in catalytic, binding and transcriptional functions (Supplementary Figure S2). A large fraction (20%) 
of the target genes is found to be transcription factor indicating probable silencing of critical factors under cis-
platin resistance scenario. Figure 8 shows miRNA-mRNA regulatory network, involving deregulated (up/down) 
miRNAs and their deregulated targets (fold change: >2.0x; p ≤ 0.05) in cisplatin resistant scenario. 7 signalling 
cross-talk proteins (octagon shape) and 3 rate limiting enzymes (triangle shape) are found to be deregulated 
under cisplatin resistance in various multi cancer cell lines. Interestingly, ATP-binding cassette (ABC) trans-
porter family, Baculovirus Inhibitor of apoptosis Repeats Containing genes (BIRC family), are also found to be 
upregulated and WNT/β -catenin pathway related genes (DKK1, DKK3, GSK3β , TCF4 etc) are also found to be 
altered significantly in multiple cancer cell lines (Fig. 8 and Supplementary Table S8) under cisplatin resistant 
condition. Similarly, CSC marker CD44 expression is also found to be upregulated. Expression fold changes of 
the target genes of 6 commonly deregulated miRNAs are provided in Supplementary Table S9. All these results 
revealed the resistance specific signature of miRNAs which might have an intricate role in the development of 
cisplatin-resistant oral cancer cells with CSC and EMT-type properties.
Discussion
One of the greatest impediments in improving the survival rates of head and neck cancer patients after sin-
gle/multimodality (surgery, chemotherapy and radiotherapy) treatment has been a lack of understanding of the 
mechanisms by which residual cells (resistant) survive from the heterogeneous cell population of the tumour 
after treatment. On the other way, the presence of cancer stem cells in association with drug resistance and EMT 
in these heterogeneous (cellularly and molecularly) population are frequently overruled by the treatment regime 
and thus responsible for disease relapse and metastasis15,16. Therefore, the understanding of the resistance mech-
anisms to chemo-radiation-therapy is indispensable and a systemic attempt is needed to improve the outcome 
Figure 4. Cisplatin-resistant (SCC131/R and SCC084/R) cells show increased spheroid formation and 
self-renewal property. Cells were seeded on ultra low attachment plates in sphere forming media. The sphere-
forming ability of cells was evaluated after 10 days under microscope (4Χ magnification). Upper panel: SCC084 
and SCC084/R cells; Lower panel: SCC131 and SCC131/R cells. These are the representative images of three 
independent experiments.
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of the head and neck cancer patients. Recent reports suggested that the short/long term exposure of cisplatin 
treatment leads to the enrichment of residual cells with cancer stem-like cells in association with EMT in differ-
ent solid tumours23,24. The novelty of the present study is the use of cisplatin-resistant cell lines of two different 
parent cell lines originated from recurrent and primary tumours of OSCC patient, to dissect out the cellular 
mechanisms responsible for survival and the subsequent behaviour of cisplatin-resistance in OSCC and here we 
establish the association of CSC specific markers, EMT and cellular migration with the survival mechanism of 
resistant OSCC cells. Furthermore, in the present study, we compared the differential profiles of miRNAs between 
cisplatin-resistant and their parental OSCC cell lines and try to correlate with their functionality.
In this study, we have developed two cisplatin-resistant (SCC084/R and SCC131/R) cell lines from their paren-
tal (SCC084 and SCC131) cell lines and characterised them in terms of their proliferative, clonogenic survival 
ability, apoptotic potential, and cell cycle distribution. Apart from the fold change in cisplatin-resistance (R index; 
Supplementary Table S2) compared to respective parental cell line we have found that as SCC084 which was orig-
inated from the recurrent tumour has 3.5 fold higher IC50 value than SCC131 originated from primary tumour 
and in turn, all these reflect the actual pathological scenario. As cancer cells undergo adaptive changes, molecular 
characterisation of these cells was aimed to identify their survival mechanisms after resistance development in 
these OSCC cells. We have found that SCC131/R resistant cells were exacerbating drug resistance through over-
expression of ABC-transporter efflux proteins, P-gp (ABCB1) and MRP1 (ABCC1) whereas SCC084/R might 
Figure 5. Induction of cancer stem-cell markers and EMT in cisplatin-resistant OSCC cells, SCC131/R 
and SCC084/R. (A) Representative images for changes in cancer stem-cell markers, CD44 c-Myc, Sox2 and 
Oct-4 expressions in cisplatin-resistant and parental cells. Cell lysates from (SCC131/R and SCC084/R) and 
parental (SCC131 and SCC084) were subjected to western blot analysis. Indicated protein specific antibodies 
were used to evaluate the level of cancer stem-cell markers. Relative expression values were normalized to those 
of β -actin. Western blot images are representative of three independent experiments. (B) Densitometry analysis 
of specific marker protein bands after normalization against the respective loading controls (β -actin) in resistant 
and parental cells. Data represent the mean ± SE calculated from three independent experiments. (C) Western 
blot images for EMT marker, E-cadherin protein expression was significantly decreased in cisplatin-resistant to 
parental cells whereas the differentiation marker Involucrin protein was also reduced significantly in cisplatin-
resistant cells. Relative expression values were normalized to those of β -actin. Images are representative of 
three independent experiments. (D) Densitometry analysis of protein bands after normalization against the 
respective loading controls (β -actin) in resistant and parental cells. Data represent the mean ± SE calculated 
from three independent experiments. (E) mRNA expression level of BMI1 and MMP9 in both the resistant 
(SCC131/R and SCC084/R) cells compared to their parental (SCC131 and SCC084) cells. Total RNA isolated 
was reverse transcribed and the cDNA subjected to qRT-PCR using gene specific forward and reverse primers. 
Relative expression values were normalized to those of 18 s rRNA (endogenous control). Data represent three 
independent experiments and expressed as mean ± SE. *p < 0.05, **p < 0.01, ***p < 0.001.
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have the other resistance mechanism. Therefore, next we screened for some survival signalling pathway specific 
proteins like survivin (encoded by BIRC5), β -catenin (encoded by CTNNB1) and NOTCH1, those were found 
to be up-regulated in different malignancies and sometimes showed correlation with poor prognosis6,9,16. In our 
present investigation we observed a significant up-regulation of survivin and β -catenin in the cisplatin-resistant 
SCC084/R and SCC131/R cells compared to parental SCC084 and SCC131 cells. Whereas NOTCH1 gene expres-
sion showed no change in these two resistant OSCC cell lines suggesting the possibilities of other molecules in 
Notch signalling to be involved in this process. Accumulating evidences also revealed a strong correlation with 
the increased expression of these proteins, survivin and β -catenin with the poor progression of patients with 
solid tumour malignancies25–28. The survivin is highly tumour-specific molecule and its up-regulation in tumours 
caused the poor response to chemo-radiation therapy25. β -catenin is one of the key modulator of cancer cells 
and responsible for creating a suitable niche for cancer progression by modulating tumour-microenvironment28. 
β -catenin directly regulates the expression of survivin and associated with the characteristic signature of stem-like 
cell populations in cancer26–28. Computational analysis of the deregulated miRNA-mRNA network suggests 
deregulation of multiple important target genes in sync with their regulatory miRNA expression status. In sup-
port of the experimental observations of this study, upregulation of ATP-binding cassette (ABC) transporter fam-
ily, Inhibitors of apoptosis containing genes (BIRC family), and CSC marker CD44 expressions are also suggested 
via computational analysis.
In the present study, we have found a significant enrichment of CSC-like cells with an increase in their 
self-renewal and tumourosphere formation capacity in cisplatin-resistant SCC084/R and SCC131/R cells. Equally, 
an increase in the CSC markers (CD44, c-Myc, and Oct-4) in these resistant cells demonstrated an enrichment 
of cells with CSC-like nature further substantiating our finding at functional protein level. In several reports 
CD44, c-Myc and Oct-4 are predicted as a poor prognostic marker in different malignancies24,29–31. In our obser-
vation we found that CD44 expression was considerably high in recurrant-origin SCC084/R cell line compared 
to primary tumour-origin SCC131/R cell line. Similar observation also substantiates our data and revealed that 
CD44 expression is correlated with local recurrence in oral cancer24,30, whereas c-Myc overexpression predicts 
aggressive transformation and poor outcome in lymphomas and other malignancies30,31. Another study on breast 
cancer reported that Oct-4 promote the EMT of CSCs and are associated with poor prognosis32. In addition, 
significant reduction in expression of E-cadherin and involucrin in association with significant increase BMI1 
and MMP9 expression in cisplatin-resistant SCC084/R and SCC131/R cells further authenticate our observation 
on spindle-shaped mesenchymal-like cellular transformation towards EMT as well as enrichment of CSC-like 
Figure 6. Cellular migration was enhanced remarkably in cisplatin resistant cells. The migration 
potentiality of resistant and parental OSCC cells was evaluated under microscope (10Χ magnification) by 
scratch assay in presence or absence of cisplatin. Drug treatment was done for 24 hrs before the scratches 
made. (A) Upper left panel shows representative images of scratch assay using SCC084 and SCC084/R cells 
respectively taken at 0 h and 20 h after the scratch made in presence or absence of cisplatin treatment. The upper 
right panel shows the quantification of cell migration (% of scratched areas) after 20 hrs calculated using Image 
J in SCC084 and SCC084/R cells. (B) Lower left shows representative images of scratch assay using SCC131 
and SCC131/R cells respectively taken at 0 h and 20 h after the scratch made in presence or absence of cisplatin 
treatment. The lower right panel shows the quantification of cell migration (% of scratched areas) after 20 
hrs calculated using Image J in SCC131 and SCC131/R cells. Images are representative of three independent 
experiments. In the bar-diagram the data expressed as mean ± SE. *p < 0.05, **p < 0.01, ***p < 0.001.
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behaviour. All these molecular expression has strong correlation with EMT, invasion and metastasis and overall 
poor survivality in different solid tumour malignancies15,17–19. Increased level of BMI1 has been considered as a 
poor prognostic marker in oral cancer16,24. In concordance with our study, a very recent study has also reported 
that the triple (Taxol, platinum, 5-fluorouracil) drug-resistance, mediated through P-gp (MDR-1), MRP-2 and 
survivin, is coupled with the acquisition of cancer stem cell behaviour in association with induced EMT in head 
and neck cancer and they suggested that acquired drug-resistance is probably achieved by induction of these 
molecules through multiple EMT and CSC-mediated pathways and showed significant correlation with the prog-
nostic outcome of the patient24. Therefore, the results from the present investigation (experimental studies and 
bioinformatic studies) concludes that Wnt-pathway/β -catenin-survivin axis might play a significant role in devel-
opment of resistance phenotype in both the cell line by up-regulating ABC-transporter P-gp, MRP1 together 
with enrichment of the CSC-like cells (CSC markers CD44, c-Myc, Oct-4 overexpression) in conjunction with 
inducing EMT (through E-cadherin down-regulation and BMI1, MMP9 up-regulation) and cellular migration.
Figure 7. Cisplatin-resistant specific miRNA selection from cisplatin-resistant and parental OSCC cell 
lines and validation by means of in vitro (altering the endogenous miR-level) and in vivo (using clinical 
samples) analysis. (A) Cluster of 36 miRNAs (listed on the right) which show significant differences (p ≤ 0.05) 
in the expression profile in SCC084/R cells compared with that in SCC084 cells. (B) Cluster of 12 miRNAs 
(listed on the right) which show differential expression profile in SCC131/R cells compared with that in SCC131 
cells. In figure (A,B) heatmap was generated using the normalized expression values (z-score of ∆ CT) of those 
significantly (p ≤ 0.05) differentially expressed miRNAs. Each column represents the expression values of 
miRNAs from an independent experiment (two different passages of the cell line were used and displayed 
as Expt 1 and Expt 2) with three technical repeats. (C) Venn diagram on total number (in parenthesis) and 
overlapping number of differentially expressed genes calculated in the cell line pairs consisting the cisplatin 
resistant to their parental cells. (D) Box plots of endogenous levels of six resistance specific miRNAs in primary 
tumour (PT, n = 6), neoadjuvant chemotherapy treated tumours (CT, n = 4) and recurrent rumours (RT, 
n = 5) in patients with OSCC. Total RNA was isolated and subsequently used for quantitative real time-PCR. 
The negative values of miRNA expression (− ∆ ∆ CT) were plotted after normalisation to the expression of 
U6 (endogenous control) and to the expression of miRNA in adjacent normal tissues. (E) MTT assay was 
used to validate the role of miR-134 in resistance development, the resistant (SCC084/R; SCC131/R) and 
parental (SCC084; SCC131) cell lines through altering its endogenous level of miR-134 expression. Cells were 
transfected either with miRNA mimic or miRNA inhibitor or control (Mock) using Lipofectamine 2000. Cells 
were subsequently treated with cisplatin after transfection and incubated for 48 hrs. Then cell viability was 
measured to assess the cisplatin mediated cytotoxicity in miR-134-overexpression and -inhibition condition in 
these OSCC cell lines. Data represent three independent experiments and expressed as mean ± SE. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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A number of studies have been recently carried out to elucidate the pattern of miRNA expression contribute 
to phenotypic outcome in OSCC patients11,12,33. In our present study, we demonstrated differential expression 
profile of miRNA in cisplatin-resistant oral squamous cell carcinoma cell lines. In the present study we profile 
only those miRNAs (52 miRNAs) which are found to be dysregulated in HNSCC patient (PhenomiR database 
v2.0)20 presuming that these miRNAs have significant role in tumourogenesis process in oral cancers. The results 
revealed that SCC084/R cell line having recurrent-tumour origin show dysregulation in 36 miRNAs compared 
to parental SCC084 cell line (Supplementary Table S4). Among them 35 miRNAs are significantly (p ≤ 0.05) 
down-regulated and only one miRNA (miR-491) is up-regulated in SCC084/R cells. Whereas 12 miRNAs 
(3 miRNAs down-regulated and 9 miRNAs up-regulated) are differentially expressed (p ≤ 0.05) in SCC131/R cell 
line having primary-tumour origin when compared to SCC131 cell line (Supplementary Table S4). There are 6 
miRNAs, miR-130b, miR-134, miR-149, miR-491, miR-181d, miR-146b, which are common in both the resist-
ant cells. However, the miRNA expression pattern is not exactly same in both cases (Supplementary Table S5). 
Although, the miR-181d and miR-146b are significantly changed in both the resistant cell line, both the miR-
NAs are up-regulated in SCC131/R cells while these are down-regulated in SCC084/R (Supplementary Table S5). 
These differences in expression pattern may be due to the distinct resistance mechanism in these two cell lines 
originated from distinct tumour-type (primary and recurrent) of OSCC patients (Supplementary Table S1). 
Moreover, recent studies also revealed that the different cancer etiology may affect miRNA expression machin-
ery differently28. In our study, the recurrent (more aggressive) patient sub-group showed significant changes in 
resistance specific miRNA expressions when compared to those of primary tumours in OSCC patients. However, 
the point to be noted that the differential factors like etiological factors, primary site, stage, grade, and treatment 
regimen were different among patient sub-groups.
Previous studies found that miR-130b is significantly deregulated in various tumour types including gastric 
cancer, pancreatic cancer, and endometrial cancer34–36. Moreover, a recent study revealed that in pancreatic cancer 
miR-130b could be a biomarker to predict the prognosis and progression of the patients as the down-regulated 
miR-130b was correlated with worse prognosis, lymphatic invasion and distant metastasis in pancreatic can-
cer33. Consistent to our results, earlier studies on miR-134 also revealed the similar results, comparatively low 
Figure 8. Regulatory network of deregulated miRNA-mRNAs in cisplatin resistant condition. Size of the 
nodes in the network are weighted based on degree (number of mRNA targets) of 26 deregulated miRNA 
(square shape) and involvement of 144 mRNA target genes/proteins in signalling/metabolic pathways where 
signalling cross-talk proteins are shown as octagon shape and rate limiting enzymes in triangle. Colour of the 
nodes is dependent on their expression fold change (fold change: >2.0 x; p ≤ 0.05). Commonly deregulated 
miRNA’s whose target genes exhibit significantly higher deregulation (fold change: 2.0 x; p ≤ 0.05) expression in 
multi cancer cell lines are marked by *.
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expression of miR-134 correlates with the invasive potential and EMT phenotype of HNSCC37 and non small 
cell lung carcinoma (NSCLC) cells38. Functional assays showed that miR-134 inhibits EMT in NSCLC cells and 
Forkhead box protein M1 (FOXM1), a potential metastasis promoter, was a direct and functional target of miR-
13438. Also low expression of cell-free miR-134 in lung adenocarcinoma-associated metastatic malignant pleural 
effusion (MPE) is correlated with poor survival39. Recent genome-wide screening identified that miR-134 acts 
as a metastasis suppressor by targeting integrin-β 1 in hepatocellular carcinoma40. Similarly studies also revealed 
that miR-149 is correlated with cell migration, invasion and EMT by targeting FOXM1 in colorectal cancer41, 
NSCLC42. In addition, down-regulated miR-149 has been shown to be associated in the crosstalk between tumour 
cells and stroma modulating the tumour-microenvironment and responsible for the tumour initiation and 
growth in a very recent study43. Cancer-associated fibroblasts (CAFs) in tumour stroma enhanced EMT and the 
CSC-like properties of gastric cancer cells in a miR-149-IL-6-dependent manner43. On the other hand, IL-6 has a 
very important role in development of drug resistance in cancer and correlated with the poor disease-outcome9. 
Corroborating our findings this has been reported that the expression of miR-146b (low or high) in cancers has 
been associated with prognosis of the disease. Up-regulation of miR-146b-5p in human tumours was found to 
be associated with aggressiveness and poor overall survival in NSCLC44, human papillary thyroid carcinoma45, 
and in muscle-invasive bladder cancer (MIBC)46. In contrary it has also been found that low expression of miR-
146b-5p predicts poor prognosis and poor outcome of large B-cell lymphoma treated with cyclophosphamide, 
doxorubicin, vincristine and prednisone47. Similarly, there is an evidence of low level of miR-146b-5p responsible 
for the prometastatic process through AUF1 gene expression and miR-146b-5p expression positively regulate the 
epithelial markers (E-cadherin, EpCAM) and repress the mesenchymal markers (N-cadherin, vimentin, twist2 
and ZEB148. Consequently, the level of miR-181d expression also revealed as a putative biomarker for lymph-node 
metastasis of oral cancer49, and correlated with clinicopathological features in ovarian cancer50 and suggested as 
a predictive biomarker for glioblastoma51. miR-181d was found to be up regulated in breast cancer compared to 
normal adjacent tumour tissues52. However, miR-491-5p displayed a significantly low level of expression in pan-
creatic cancer cell and mediated cell apoptosis by targeting both Bcl-xL and TP5353. In consistent with our results, 
a report also suggested that the level of miR-491-5p expression correlated inversely with GIT1, which in turn is 
correlated with lymph node metastasis and tumour grade in OSCC clinical samples and finally they suggested 
miR-491-5p and GIT1 as biomarkers for prognosis in this cancer54. Keeping in mind the background evidences 
and in light of the current results, (as in Supplementary Table S9) we can suggest that the microenvironment 
required for the development of these OSCC resistant cell lines with all these particular phenotype is probably 
created by these resistance specific miRNA expression signature patterns through modulating their target gene 
expression in OSCC .
In conclusion, in the present study we have demonstrated 6 differentially expressed miRNAs signature pat-
tern in two cisplatin-resistant OSCC cell lines those were enriched with the cancer-stem-cell-like characteristics 
sometimes in association with drug efflux transporters mediated drug-resistance through inducing EMT and cell 
migration. In addition, we can envisage that these cellular transformation and miRNAs expression pattern might 
have some correlation with the patient outcome. Consequently, these expression patterns most likely anticipated 
as useful prognostic biomarker for oral cancers.
Materials and Methods
Cell lines and induction of cisplatin-resistance in OSCC cells. The human oral squamous cell carci-
noma cell lines, SCC084 and SCC131 were purchased from Dr. Susanne Gollin (University of Pittsburgh, USA) 
(Supplementary Table S1)14. All OSCC cells were grown in DMEM/F12 (1:1) (Gibco, Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% FBS (Gibco, Life Technologies), 1% L-glutamine (Gibco, Life Technologies), 
1% antibiotic mixture (Penicillin-Streptomycin-Neomycin or PSN; Gibco, Life Technologies) and 0.006% 
Gentamicin (Gibco, Life Technologies) at 37 °C in a humidified 5% CO2 incubator.
Cisplatin [cis-diamminedichloroplatinum (II), CDDP] was obtained from Sigma-Aldrich and dissolved in 
PBS. Aliquots were stored at 4 °C and used for 7 days. In accordance with previously described methods55 cispla-
tin resistant SCC084/R and SCC131/R (pooled clones) were developed from their parental cell line SCC084 and 
SCC131 respectively by gradual incremental doses of cisplatin administration in cell culture medium in subse-
quent passages for about 6–8 months. Thereafter SCC084/R and SCC131/R cells were maintained in presence 
of 1 μg/ml (3 μM) cisplatin in cultured medium for 48 h in every alternate passage. In case of resistant cell lines, 
any experiment was set up with cells when those were grown in drug-free culture medium. All the resistant were 
cultured in the same conditions as parental OSCC cell lines.
Cytotoxicity assay. Cytotoxic effect of cisplatin was measured by MTT assay. Cells were seeded in 96-well 
plates at a density 2 × 104 for SCC084 and SCC084/R and 1 × 104 for SCC131 and SCC131/R cells per well. The 
cells were incubated overnight at 37 °C to allow adhere and recovery. Increasing concentrations of cisplatin was 
administered for each cell line and incubated for different time points like, 24 h, 48 h and 72 h with 5% CO2 at 
37 °C. After completion of incubation, 4 μl of a 5 mg/ml solution in PBS of MTT dye (3-[4,5-dimethylthiazol- 
2-yl]-2, 5-diphenyltetrazolium bromide; Sigma) was added to each well and incubated for 4 h at 37 °C. The media 
discarded and the resulting violet formazan precipitate was dissolved in 100 μl of DMSO. The colour absorbance 
was recorded at 540 nm by microplate reader (Multiskan Ex). The control value corresponding to untreated cells 
was taken as 100% and the viability of treated samples were expressed as a percentage of the control. The IC50 val-
ues were determined as the concentration that reduced cell viability by 50%. The degree of resistance is evaluated 
in terms of resistance index, R (R = IC50 values of resistant cells/ IC50 values of parental cells).
Clonogenic survival assay. The sensitivity of SCC084, SCC131, SCC084/R and SCC131/R cells to cisplatin 
was measured using the clonogenic assay or colony formation assay based on the ability of a single cell to grow 
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into a colony. For each cell lines 500 cells were seeded in each well of a 6 cm dish and allowed to adhere overnight 
at 37 °C and treated with different doses of cisplatin for 24 h. Then medium was changed to drug free medium 
and cells were allowed to grow into colonies within next 7–14 days. Colonies were analysed microscopically and 
fixed and stained with 0.2% methylene blue (Sisco Research Laboratories, Mumbai, India) in PBS and washed 
with water. The colonies were then counted using Image J software and the number of colonies was calculated as 
mean of three independent experiments.
Cell cycle analysis. 2 × 105 cells were seeded in 60 mm dish and treated with different doses of cisplatin 
for 72 h. Cells were collected by tripsinization and washed twice in PBS, fixed in 70% chilled ethanol by adding 
dropwise into the samples while vortexing and stored at 4 °C until analyzed. Immediately before analysis, cells 
were washed twice in PBS, and incubated with 250 μg/ml RNase A (Invitrogen) for 30 min at room temperature, 
followed by staining with PI (Sigma) at 20 μg/ml final concentration for 30 min incubation in dark. The cell cycle 
distribution and percentage of apoptotic cells were analysed using a FACS analyser (BD LSRFortessa). Ten thou-
sand cells were analysed for each sample. Appropriate gating was used to select the single-cell population. The 
percentage of cells in sub-2n phase was determined using software (BD FACSDiva v6.0).
Annexin V-PI binding assay. Apoptosis was determined by annexin V/ PI staining with the apoptosis 
detection kit (BD Pharmingen). 1 × 105 cells were treated with different doses of cisplatin for 72 h. Cells were 
collected by tripsinization and washed twice in PBS. Cells were stained with Annexin V- FITC and PI at room 
temperature for 15 min in the dark and analyzed by FACS using two-colour FACS analysis (BD LSRFortessa).
Flow Cytometric analysis of putative ABC-transporters. Cisplatin-resistant and parent cells (1 × 106) 
were collected by trypsinization and washed twice in PBS containing 1% FBS and pellet by centrifugation at 
1500 rpm for 3 min. Dual staining for P-glycoprotein (P-gp) and Multi-drug Resistance-associated Protein-1 
(MRP-1) was carried out. Cells were incubated with mouse monoclonal P-gp antibody (UIC2) (Santa Cruz 
Biotechnology) and then with PE-conjugated secondary antibody and subsequently by FITC-conjugated mouse 
monoclonal MRP-1 antibody (BD Biosciences). Cells were washed briefly and resuspended in PBS for subsequent 
analysis. Samples were acquired (10,000 cells) and analysed by FACS (BD LSRFortessa) and the percentage of 
P-gp and MRP-1 positive cells were calculated.
Confocal microscopic analysis for ABC-transporters. The levels of P-gp and MRP1 expression were 
also analyzed by mouse monoclonal anti P-gp antibody (C219) (Calbiochem, USA) and FITC-conjugated mouse 
monoclonal MRP-1 antibody (BD Biosciences) respectively. Briefly, SCC131/R and SCC131 cells (0.5 × 106 cells) 
were platted on cover slips for confocal microscopy in labeled groups and cultured overnight followed by fixing 
of the cells on cover slips with 4% paraformaldehyde. The cells were incubated with P-gp antibody (C219) for 
two hours. Following incubation, the cells were washed twice with PBS containing 0.1% FBS and re-incubated 
with PE-conjugated 2° antibody (anti mouse) for another 1 hr. Cells were then subsequently incubated with 
FITC-conjugated MRP-1 antibody (BD Biosciences) for another two hours. Cells were washed twice with PBS 
(containing 0.1% FBS) and mounted with antifade mounting media with Dapi-Dabco (Life Technologies) and 
analyzed in confocal microscope (Andor Spinning Disc Confocal) using Andor iQ 2.7 software for assessing the 
level of P-gp and MRP1 expression.
Drug accumulation assay. The fluorescent property of doxorubicin, a good substrate for P-gp, was used 
for drug accumulation assay56. SCC131/R and SCC131 cells (0.5 × 106 cells) were platted on cover slips in 2 ml of 
complete growth media and left overnight. Fresh media was changed to each group prior to initiate experiment 
and incubated with doxorubicin (10 μM) at 37 °C for 1 hr. The cells were fixed with 4% paraformaldehyde and 
washed with PBS containing 0.1% FBS and mounted with glycerol and analyzed immediately for intracellular 
accumulation of doxorubicin using confocal microscope (Andor Spinning Disc Confocal) and Andor iQ 2.7 
software.
Sphere forming assay. Cells (2 × 104/well) were seeded on ultra-low attachment 6-well plates in serum free 
DMEM/F12 media supplemented with growth factors. The sphere forming medium was supplemented with 1% 
B27 supplement (Invitrogen Gibco), 20 ng/ml of human recombinant epidermal growth factor (EGF), 20 ng/ml 
human basic fibroblast growth factor (b-FGF) and 1% penicillin-streptomycin. The sphere forming ability of the 
cells was recorded on next 7–14 days. Size and number of spheres were assessed under Leica microscope.
Cell migration assay. The migratory potential of cells was assessed by the wound-healing scratch assay. 
2 × 105 cells were plated in each well in 6-well plates. Cells were treated with cisplatin for 48 h. After completion 
of incubation a scratch has been made with sterile 200 μl tip and washed cells twice with PBS and restore with 
drug-free fresh media. Photos were taken of the scratches at 0 h and 20 h using Leica microscope. The percent of 
cellular migration after scratches made was quantified using Image J software.
Western blot. Cells plated at high seeding in 10 cm dish were allowed to grow to 90% confluent within 
3–4 days. Whole cell lysates having equal protein concentrations were resolved by SDS/PAGE (8–12%) and 
transferred onto a PVDF (Millipore, Billerica,USA) membrane. Various antibodies used were rabbit mono-
clonal survivin (Cell Signalling Technology), rabbit polyclonal β -catenin (H-102) (Santa Cruz Biotechnology), 
rabbit polyclonal E-cadherin (H-108) (Santa Cruz Biotechnology), rabbit polyclonal involucrin (Santa Cruz 
Biotechnology), mouse monoclonal CD44 (H-CAM, DF1485) (Santa Cruz Biotechnology), rabbit polyclonal 
c-Myc (Cell Signalling Technology), rabbit polyclonal Sox-2 (Abcam), rabbit polyclonal Oct-4 (Abcam), mouse 
monoclonal β -actin (Sigma), rabbit polyclonal PARP 1 (Cell Signalling Technology), mouse monoclonal Caspase 
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3 (E-8, Santa Cruz Biotechnology), mouse monoclonal α -tubulin (Santa Cruz Biotechnology). Bands were 
detected using super signal west pico chemiluminescent substrate (Thermo Scientific, USA) after treating with 
HRP-cojugated secondary antibody (Sigma).
Quantitative Real-Time PCR (qRT-PCR) and RT-PCR. SYBR green qRT-PCR assay was used for 
miRNA profiling and gene expression analysis by using 7500 Fast real-time PCR system (Applied Biosystem). 
Total RNA was isolated from cultured cells using the TRIzol reagent (Invitrogen). To analyse the mature miRNA 
expression, 1 μg total RNA was used for cDNA synthesis by using the 5x miScript HiSpec buffer in miScript II RT 
kit (Qiagen) according to manufacturer’s instructions. Then PCR product was diluted and 1 ng cDNA was used 
per reaction for quantitative real-time PCR by using specific miScript primer assays/miRNA specific forward 
primer (Supplementary Table S10) and miScript Universal primer provided in the miScript SYBR Green PCR 
kit (Qiagen) following the manufactures protocol. RNU6B (U6) served as an endogenous control for miRNA 
expression analysis. All reactions were performed in triplicate with two biological repeats. The cycle threshold 
(CT) (considered only the value which is < 35) is defined as the number of cycles required for the fluorescent 
signal to cross the threshold in qPCR. ∆ CT was calculated by subtracting the CT values of U6 from the CT val-
ues of miRNA of interest. ∆ ∆ CT was then calculated by subtracting ∆ CT of the parental cells (control) from 
∆ CT of cisplatin-resistant cells (sample). Fold change of each miRNA expression was calculated by comparative 
method using the equation 2−∆∆CT. All the real-time PCR data of miRNA expression were analysed using the 
Bioconductor Limma packages for two different cell lines separately. Unsupervised hierarchical clustering based 
upon Euclidean distances was performed on cisplatin-resistant cell lines. Finally, normalized expression values 
of those significantly (p ≤ 0.05) differentially expressed miRNAs were used to draw heatmap using R software 
(version 3.2.1).
To check the gene expression, cDNAs were synthesized from 1 μg of total RNA using Verso cDNA synthesis 
kit (Thermo Scientific) according to manufacturer’s protocol. Quantitative RT-PCR was performed by mixing 
5 ng of cDNA with SYBR Green PCR Master Mix (Roche) and various sets of gene specific primers (forward and 
reverse) (Supplementary Table S11). In this case, 18 S rRNA was used as an endogenous reference control. Then 
these were subjected to RT-PCR quantification by using the 7500 Fast real-time PCR system (Applied Biosystem). 
All reactions were performed in triplicate. The relative amounts of mRNA were calculated same as miRNA by 
using the comparative CT method. The results are presented as relative expression of fold change of each mRNA 
in cisplatin-resistant cells to their parental cells.
miRNA mimic and miRNA inhibitor transfection. Cisplatin-resistant and sensitive cells (4 × 104 cells/
well) were seeded in 24 well plates. Next day OSCC cells were transfected either with 5 nM of miRNA mimic 
(Qiagen) or 50 nM of miRNA inhibitor (Qiagen) or mock (control) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) in Opti-MEM reduced serum medium (Invitrogen Life TechnologiesInc., Carlsbad, CA) according 
to the manufacture’s protocol. After 6 hrs, media replaced with DMEM supplemented with antibiotics and 10% 
FBS and drug treatment done and incubated for 48 hrs.
Patient samples. Oral cancer biopsies and surgical tumour samples with adjacent normal tissues were 
obtained from the hospital section of Chittaranjan National Cancer Institute (CNCI), Kolkata, India. Prior 
to sample collection, written informed consent was taken from each patient. The study was approved by the 
Institutional Ethics Committee of CNCI and carried out in accordance with the approved guidelines. For the 
present study we have selected specific patient sub-groups like OSCC-patients with newly diagnosed primary 
tumour (PT; n = 6), neoadjuvant chemotherapy treated tumour (CT; n = 4), and recurrent tumour (RT; n = 5). 
Here we have selected only those patients who have given cisplatin in their neoadjuvant chemotherapy cycle 
before surgery. Whereas in recurrent patient, the treatment regimen may differ (with or without chemotherapy 
and/or radiotherapy). Anticipating the idea, the recurrent tumours will be more aggressive or resistant to therapy 
compared to other two groups. Detailed patient history is provided in Supplementary Table S6. Total RNA was 
isolated from patient’s samples using tissue lyser (TissueLyser LT, QIAGEN) and RNeasy Plus mini kit (Qiagen). 
To analyse the mature miRNA expression the protocol was same as before by using miScript II RT kit (Qiagen) 
and miScript SYBR Green PCR kit (Qiagen). The negative expression values of a particular miRNA (− ∆ ∆ CT) 
was plotted in the box plot after normalisation to the U6 (endogenous control) expression and to the specific 
miRNA expression in adjacent normal tissue samples with the respective tumour sample using R software (ver-
sion 3.2.1). The significance of miRNA expression level was determined by the Mann-Whitney test.
Collection of mRNA target genes for deregulated miRNAs. Experimentally known target mRNAs 
of the deregulated miRNAs were collected from the miRTarBase database22. 42 miRNAs were found to be dif-
ferentially expressed in SCC084/R and SCC131/R cell lines relative to their parental SCC084 and SCC131 lines, 
respectively. Fold change of their target mRNA expression in cisplatin resistant Vs sensitive scenario was col-
lected from various multi cancer cell line data available in ONCOMINE database21 (Supplementary Table S12). 
Differentially expressed (fold change: >2.0x; p ≤ 0.05) mRNAs were used to create the miRNA-mRNA regulatory 
network using the Cytoscape software57. Functional categorization of the target mRNAs were performed using 
Gene Ontology (GO)58 molecular functions extracted from the Panther database59.
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